Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase

Osteoarthritis and Cartilage

Volumn 6, Issue 3, 1998, Pages 214-228

  Arner, Elizabeth C ^a   Hughes, Clare E ^b   Decicco, Carl P ^a   Caterson, Bruce ^b   Tortorella, Micky D ^a  

^a DUPONT COMPANY   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aggrecanase; Cartilage; Cytokines; Matrix metalloproteinase; Proteoglycan degradation

Indexed keywords

AGGRECAN; AGGRECANASE; DEXAMETHASONE; DOXYCYCLINE; INDOMETACIN; INTERLEUKIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BC 3; NAPROXEN; TENIDAP; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CATTLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE TIME EFFECT RELATION; ENZYME ANALYSIS; ENZYME BINDING; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEOGLYCAN SYNTHESIS;

EID: 0032076280     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1053/joca.1998.0114     Document Type: Article

References (53)

1. 1. Mankin HJ, Lippiello L. Biochemical and metabolic abnormalities inarticular cartilage from osteo-arthritic human hips. J Bone Joint Surg[Am] 1970;52:424-34.
2. 2. Sandy JD, Boynton RE, Flannery CR. Analysis of the catabolism ofaggrecan in cartilage expiants by quantitation of peptides from the three globular domains. J Biol Chem 1991;266:8198-205.
3. 3. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992;267:19470-4.
4. 4. Flannery CR, Lark MW, Sandy JD. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 1992; 267:1008-14.
5. 5. Sandy JD, Flannery CR, Neame PJ, Lohmander LS. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu373-Ala374 bond of the interglobular domain. J Clin Invest 1992;89:1512-6.
6. 6. Lohmander LS, Neame PJ, Sandy JD. The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, andosteoarthritis. Arthritis Rheum 1993;36:1214-22.
7. 7. Sandy JD, Neame PJ, Boynton RE, Flannery CR. Catabolism of aggrecan in cartilage expiants. Identification of a major cleavage site within the interglobular domain. J Biol Chem 1991;266: 8683-5.
8. 8. Loulakis P, Shrikhande A, Davis G, Maniglia CA. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymatic cleavage. Biochem J 1992; 284(Pt 2): 589-93.
9. 9. Ilic MZ, Handley CJ, Robinson HC, Mok MT. Mechanism of catabolism of aggrecan by articular cartilage. Arch Biochem Biophys 1992;294:115-22.
10. 10. Lark MW, Gordy JT, Weidner JR, Ayala J, Kimura JH, Williams HR et al. Cell-mediated catabolism of aggrecan. Evidence that cleavage at the 'aggrecanase' site (Glu373-Ala374) is a primary event in proteolysis of the interglobular domain. J Biol Chem 1995;270:2550-6.
11. 11. Fosang AJ, Last K, Knauper V, Neame PJ, Murphy G, Hardingham TE et al. Fibroblast and neutrephil collagenases cleave at two sites in the cartilage aggrecan interglobular domain. Biochem J 1993;295:273-6.
12. 12. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ. Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996;380: 17-20.
13. 13. Flannery CR, Sandy JD. Aggrecan catabolism in cartilage: studies on the nature of a novel proteinase (aggrecanase) which cleaves the Glu373-Ala374 bond of the interglobular domain. Trans Orthop Res Soc 1993;18:190.
14. 14. Fosang AJ, Last K, Neame PJ, Murphy G, Knauper V, Tschesche H et al. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan. Biochem J 1994;304:347-51.
15. 15. Arner EC, Decicco CP, Cherney R, Tortorella MD. Cleavage of native cartilage aggrecan by neutrophil collagenase (MMP-8) is distinct from endogenous cleavage by aggrecanase. J Biol Chem 1997;272:9294-9.
16. 16. Chubinskaya S, Huch K, Mikecz K, Cs-Szabo G, Hasty KA, Kuettner KE, Cole AA. Chondrocyte matrix metalloproteinase-8: up-regulation ofneutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. Lab Invest 1996;74:232-40.
17. 17. Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995;305:799-804.
18. 18. Huang JJ, Newton RC, Pezzella K, Covington M, Tamblyn T, Rutlege SJ et al. High-level expression in Escherichia coli of a soluble and fully active recombinant interleukin-1 beta. Mol Biol Med 1987;4:169-81.
19. 19. Hughes CE, Buttner FH, Eidenmuller B, Caterson B, Bartnik. Utiliation of a recombinant substrate (rAgg1) to study the biochemical properties of 'aggrecanase' in cell culture systems. J Biol Chem 1997;272:20269-72.
20. 20. Campion C, Davidson AH, Dickens JP, Crimmins MJ. Preparation of N-(4-(N-hydroxyamino) succinyl)amino acid amides as collagenase inhibitors. November 23, 1989;PCT/GB89/01399.
21. 21. Wright SW, Petraitis JJ, Abelman MM, Batt DG, Bostrom LL, Corbett RL, Decicco CP et al. Heteroaryl-fused 2-phenylisothiazolone inhibitors of cartilage breakdown. J Med Chem 1994;37: 3071-8.
22. 22. Steinberg J, Sledge CB, Noble J, Stirrat CR. A tissue-culture model of cartilage breakdown in rheumatoid arthritis. Quantitative aspects of proteoglycan release. Biochem J 1979; 180:403-12.
23. 23. Arner EC, Pratta MA. Modulation of interleukin-1-induced alterations in cartilage proteoglycan metabolism by activation of protein kinase C. Arthritis Rheum 1991;34:1006-13.
24. 24. Hascall VC, Sajdera SW. Proteinpolysaccharide complex from bovine nasal cartilage. The function of glycoprotein in the formation of aggregates. J Biol Chem 1969;244:2384-96.
25. 25. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connect Tissue Res 1982;9:247-8.
26. 26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
27. 27. Hughes CE, Caterson B, White RJ, Roughley PJ, Mort JS. Monoclonal antibodies recognizing pro tease-generated neoepitopes from cartilage proteoglycan degradation. Application to studies of human link protein cleavage by stromelysin. J Biol Chem 1992;267:16011-4.
28. 28. Arner EC, Pratta MA. Independent effects of interleukin-1 on proteoglycan breakdown, proteoglycan synthesis, and prostaglandin E2 release from cartilage in organ culture. Arthritis Rheum 1989;32:288-97.
29. 29. Arner EC, Darnell LR, Pratta MA, Newton RC, Ackerman NR, Galbraith W. Effect of antiinflammatory drugs on human interleukin-1-induced cartilage degradation. Agents Actions 1987;21:334-6.
30. 30. Arner EC, Pratta MA, Freimark B, Lischwe M, Trzaskos JM, Magolda RL, Wright SW. Isothiazolones intefere with normal matrix metalloproteinase activation and inhibit cartilage proteoglycan degradation. Biochem J 1996;318: 417-24.
31. 31. Lark, MW, Bayne EK, Flanagan J, Harper CF, Hoerner LA, Hutchinson NI et al. Aggrecan degradation in human cartilage: evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic and rheumatoid joints. J Clin Invest 1997; 100:93-106.
32. 32. Loulakis P, Shrikhande A, Davis G, Maniglia. N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures: putative site(s) of enzymatic cleavage. Biochem J 1992;284:589-93.
33. 33. Brandt KD, Albrecht M. Effect of naproxen sodium on the net synthesis of glycosaminoglycans and protein by normal canine articular cartilage in vitro. J Pharm Pharmacol 1990;42: 738-40.
34. 34. Gentry C. The effects of the active metabolite of nabumetone (6MNA) on the synthesis of normal canine articular cartilage in vitro: comparison with other non-steroidal anti-inflamatory drugs (NSAIDS). Br J Rheumatol 1992;31(Suppl. 2):168.
35. 35. Rainsford KD. Scand J Rheumatol 1994;(Suppl.) 98:138.
36. 36. Lane NE, Williams RJ III, Schurman DJ, Smith RL. Inhibition of interleukin 1 induced chondrocyte protease activity by a corticosteroid and a nonsteroidal anti-inflammatory drug. J Rheumatol 1992;19:135-9.
37. 37. Dingle JT, Shield MJ. The interactions of cytokines, NSAIDs and prostaglandins in cartilage destruction and repair. Adv Prostaglandin Thromboxane Leukot Res 1991;21B:955-66.
38. 38. Shield MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm 1993;13:7-16.
39. 39. Steinmeyer J, Daufeldt S, Kalbhen DA. Pharmacologic influence on the activity of stromelysin from bovine articular cartilage. Ann NY Acad Sci 1994;732:482-3.
40. 40. Glazer PA, Rosenwasser MP, Ratcliffe A. The effect of naproxen and interleukin-1 on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage in vitro. J Clin Pharmacol 1993;33:109-14.
41. 41. Ratcliffe A, Azzo W, Saed-Nejad F, Lane N, Rosenwasser MP, Mow VC. In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage. J Orthop Res 1993;11:163-71.
42. 42. Cawston TE, Curry V, Ramsey S, Clark IM, Kyle VA, Adebajo A, Silverman B et al. The levels of collagenase, tissue inhibitor of metalloproteinases-1 (TIMP-1), collagenase-TIMP-1 complexes and glycosaminoglycan (GAG) in sequential samples of synovial fluid aspirated from patients with osteoarthritis. Clin Exp Rheumatol 1995;13:431-7.
43. 43. Dingle JT, Leeming MR, Martindale JJ. Effect of tenidap on cartilage integrity in vitro. Ann Rheum Dis 1993;52:292-9.
44. 44. Pelletier JP, McCollum R, DiBattista J, Loose LD, Cloutier JM, Martel-Pelletier J. Regulation of human normal and osteo arthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum 1993;36:1517-27.
45. 45. Fernandes JC, Martel-Pelletier J, Otterness IG, Lopez-Anaya A, Mineau F, Tardif G, Pelletier JP. Effects of tenidap on canine experimental osteoarthritis. I. Morphologic and metalloprotease analysis. Arthritis Rheum 1995;38:1290-303.
46. 46. Fernandes JC, Caron JP, Martel-Pelletier J, Jovanovic D, Mineau F, Tardif G et al. Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. Arthritis Rheum 1997;40:284-94.
47. 47. Srinivas GR, Chichester CO, Barrach HJ, Matoney AL. Effects of certain antiarthritic agents on the synthesis of type II collagen and glycosaminoglycans in rat chondrosarcoma cultures. Agents Actions 1994;41:193-9.
48. 48. Greenwald RA. Tetracyclines, derivatives as potential inhibitors of connective tissue degradation. Drug News & Perspect 1990;3:161-6.
49. 49. Greenwald RA, Golub LM, Lavietes B, Ramamurthy NS, Gruber B, Laskin RS, McNamara TF. Tetracyclines inhibit human synovial collagenase in vivo and in vitro. J Rheumatol 1987; 14:28-32.
50. 50. Arsenis C, Greenwald RA, Moak SA, Laskin RS. Inhibition of neutral metalloproteinase activities in epiphyseal and articular cartilages by tetracyclines both in vivo and in vitro. Trans Orthop Res Soc 1990;15:268.
51. 51. Arner EC, Decicco CP, Pratta MA, Copeland RA, Trzaskos DM, Magolda RL, Tortorella MD. Characterization of soluble bovine cartilage 'aggrecanase'. Trans Orthop Res Soc 1997;22:103.
52. 52. Black RA, Rauch CT, Koziosky CJ, Peschon JJ, Slack JL, Wolfson MF et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature 1997;385:729-33.
53. 53. Moss ML, Jin S-L C, Millia ME, Burkhart W, Carter HL, Chen W-J et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-a. Nature 1997;385:733-6.